Stuart Secker
Director/Board Member at Multiple Sclerosis Society
Stuart Secker active positions
| Companies | Position | Start | End |
|---|---|---|---|
Multiple Sclerosis Society
 Multiple Sclerosis Society Miscellaneous Commercial ServicesCommercial Services The Multiple Sclerosis Society is an organization that aims to find treatments for everyone affected by multiple sclerosis. The non-profit company is based in London, UK. The British company offers award-winning publications, factsheets, and booklets through their online shop. The society conducts surveys to shape the future direction of MS research, with the latest survey held in 2022 with over 6,500 participants. The company's current focus is on the STARMS trial, which compares HSCT with other highly effective treatments for relapsing MS. The treatment involves using chemotherapy to remove harmful immune cells and regrow the immune system using the patient's own stem cells. Nick Moberly has been the CEO of the company since 2019. | Director/Board Member | 31/08/2016 | - |
| Treasurer | 31/08/2016 | - |
Career history of Stuart Secker
Statistics
International
| United Kingdom | 2 |
Operational
| Director/Board Member | 1 |
| Treasurer | 1 |
Sectoral
| Commercial Services | 2 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
| Private companies | 1 |
|---|---|
Multiple Sclerosis Society
Multiple Sclerosis Society Miscellaneous Commercial ServicesCommercial Services The Multiple Sclerosis Society is an organization that aims to find treatments for everyone affected by multiple sclerosis. The non-profit company is based in London, UK. The British company offers award-winning publications, factsheets, and booklets through their online shop. The society conducts surveys to shape the future direction of MS research, with the latest survey held in 2022 with over 6,500 participants. The company's current focus is on the STARMS trial, which compares HSCT with other highly effective treatments for relapsing MS. The treatment involves using chemotherapy to remove harmful immune cells and regrow the immune system using the patient's own stem cells. Nick Moberly has been the CEO of the company since 2019. | Commercial Services |
- Stock Market
- Insiders
- Stuart Secker
- Experience
